Home ›
Leukemia Trials ›
NCT06017258
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
Trial Details
NCT ID NCT06017258
Phase PHASE1
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type Leukemia
Interventions CD371-specific/YSNVz/I-18 CAR T cells
Locations (sample) Basking Ridge, New Jersey, United States|40.70621,-74.54932 Middletown, New Jersey, United States|40.39428,-74.11709 Montvale, New Jersey, United States|41.04676,-74.02292 Commack, New York, United States|40.84288,-73.29289 Harrison, New York, United States|40.96899,-73.71263
Key Eligibility Criteria
Subject Inclusion: Collection of T cells (Part A) History of CD371+ AML Any disease status is eligible for collection Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →